AVEO Oncology
Biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Launch date
Employees
Market cap
-
Enterprise valuation
€515m (Public information from Oct 2022)
Cambridge Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $15.0m | Series A | |
$42.7m | Series B | ||
| N/A | $5.0m | Series C | |
| N/A | $12.5m | Series C | |
$53.0m | Series D | ||
| N/A | $20.0m | Early VC | |
| N/A | N/A | IPO | |
| N/A | $60.8m | Post IPO Equity | |
| N/A | $7.5m | Post IPO Equity | |
* | N/A | $104m | Post IPO Equity |
| N/A | $53.8m | Post IPO Equity | |
N/A | - | ||
| N/A | $17.0m | Post IPO Equity | |
| N/A | $15.5m | Post IPO Equity | |
$35.0m | Debt | ||
| N/A | $48.0m | Post IPO Equity | |
* | $566m Valuation: $566m | Acquisition | |
| Total Funding | €135m | ||
Related Content
Recent News about AVEO Oncology
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.